Kite Pharma's Lead Program With The National Cancer Institute (NCI) Demonstrates Positive Results In Patients With Aggressive Non-Hodgkin's Lymphoma
LOS ANGELES, Dec. 7, 2013 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on engineered autologous T cell therapy (eACT) products for cancer, today announced positive clinical data demonstrating that Kite's most advanced product candidate can produce robust and durable tumor shrinkage in patients with an aggressive form of non-Hodgkin's lymphoma. In an oral presentation at the 55th ASH Annual Meeting, James N. Kochenderfer, MD, from the NCI reported that an infusion of patients' own genetically modified T lymphocytes resulted in six complete remissions (CR) and six partial remissions (PR) among 13 patients with advanced B-cell malignancies who were eligible for response assessment.
Kite Pharma and the Surgery Branch of the NCI, led by Steven A. Rosenberg, MD, PhD, are collaborating under a Cooperative Research and Development Agreement (CRADA) for the development and commercialization of novel eACT products for the treatment of multiple cancer indications. This technology utilizes patients' peripheral blood T lymphocytes genetically engineered with either chimeric antigen receptors (CAR) or T cell receptors (TCR) that recognize tumor-specific molecules, traffic directly to the tumor, become activated upon engagement with the tumor antigen, and selectively eradicate tumors. The reported Phase 1/2a clinical trial is being conducted at the NCI with Dr. Rosenberg serving as principal investigator.
In the clinical trial, patients' T cells were modified to express a CAR targeting the B cell antigen CD19. Among the nine patients with either chemotherapy-refractory primary mediastinal B cell lymphoma (PMBCL) or diffuse large B cell lymphoma (DLBCL), seven patients were evaluable for response. Of these seven patients, six showed a response (three CR's and three PR's). This is the first report of successful treatment of these patients with CD19 CAR T cells. The majority of clinical responses were durable (up to 22 months ongoing). Acute toxicities, including fever, low blood pressure, focal neurological deficits, and delirium occurred in some patients after cell infusion, but resolved in less than three weeks.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts